Pharma Stocks
-
CU6) Rises 9% as Traders Rotate Into Biotech Stocks
Shares of Clarity Pharmaceuticals Ltd. (ASX: CU6) climbed 9.33% on 21 May 2026 to A$2.76 per share, registering a notable…
Read More » -
oncology focus and pipeline updates draw investor attention
Astellas Pharma has been in focus following recent oncology pipeline updates and regulatory developments, keeping the Japanese drug maker on…
Read More » -
Cenexi recovery, new product launches and capacity additions power Gland Pharma outlook
Gland Pharma has gained 19% on the bourses in the past three trading sessions to hit a 52-week high after…
Read More » -
Assessing Indivior Pharmaceuticals (INDV) Valuation After Strong Long Term Share Price Momentum
Indivior Pharmaceuticals stock after recent performance Indivior Pharmaceuticals (INDV) has drawn fresh attention after recent share performance, with the stock…
Read More » -
Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?
Shares of pharma companies rallied up to 7% on Wednesday as strong earnings, a weakening rupee, and other supportive factors…
Read More » -
FDA Approval Of Tessie Puts Orion’s Animal Health Potential In Focus
Orion Oyj (HLSE:ORNBV) has received FDA approval for its proprietary veterinary drug Tessie (tasipimidine) for use in the U.S. market.…
Read More » -
Chinese pharma player in focus after recent business u
Huadong Medicine Co Ltd has remained active with business and product updates, drawing attention to its role in China’s pharmaceutical…
Read More » -
Cosette Pharmaceuticals Appoints David Bell as Chief Commercial Officer (Brands)
Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today it has appointed David Bell as Chief Commercial Officer…
Read More » -
Aurobindo Pharma Sees Sharp Open Interest Surge Signallin…
Open Interest and Volume Dynamics The latest data reveals that Aurobindo Pharma’s open interest (OI) in derivatives rose sharply by…
Read More » -
Gland Pharma Limited Just Recorded A 8.8% EPS Beat: Here’s What Analysts Are Forecasting Next
A week ago, Gland Pharma Limited (NSE:GLAND) came out with a strong set of full-year numbers that could potentially lead…
Read More »